Background: Papillary thyroid carcinoma (PTC) is typically treated with surgical resection, even in recurrent cases. However, some cases of recurrent PTC are refractory to the conventionally used locoregional radiotherapy and resection methods. I seed permanent brachytherapy has emerged as a promising alternative for such PTCs, but no effective brachytherapy protocol has been reported for tumors with a huge volume, liquefaction, necrosis, and skin invasion.
Case Presentation: A 47-year-old man presented with recurrence 8 years after 2 thyroidectomy procedures for PTC and recurrent PTC. The tumor measured 6 × 7 × 8 cm and exhibited liquefaction, necrosis, and skin invasion. The patient was treated at our hospital from December 2017 to November 2018. He received one round of I seed temporary brachytherapy and 4 rounds of I seed permanent implantation. The activity of the seeds was 0.3-3.0 mCi, and the total dose delivered to the tumor was 145 Gy. The recurrent tumor was successfully removed by I seed brachytherapy guided with a 3D-printed template and ultrasound and CT scanning. The refractory tumor healed uneventfully after I seed brachytherapy without recurrence over the 25-month follow-up.
Conclusions: To the best of our knowledge, this is the first reported case of a large thyroid carcinoma that was effectively treated by 3D-printed template-guided I seed brachytherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647112 | PMC |
| http://dx.doi.org/10.1159/000519572 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ultra-low dose rate brachytherapy (uLDR-BT) in treatment of patients with unfavorable intermediate-risk group prostate cancer - retrospective analysis.
Rep Pract Oncol Radiother
December 2024
Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
Article Synopsis
- The study retrospectively evaluated the effectiveness of ultra-low dose rate brachytherapy (uLDR-BT) in 39 patients with unfavorable intermediate risk prostate cancer, despite current guidelines recommending against it due to insufficient evidence.
- Results showed a promising median follow-up of about 56 months, with an 87.02% biochemical failure-free survival rate, indicating uLDR-BT could be a viable treatment option.
- No significant differences in outcomes were observed based on additional risk factors or treatment methods, suggesting that uLDR-BT's effectiveness is consistent across different patient profiles in the intermediate risk category.
Dosimetric verification of point doses for I-125 implants designed by different manufacturers in prostate brachytherapy.
Rep Pract Oncol Radiother
December 2024
Department of Biomedical Physics, Faculty of Physics, Adam Mickiewicz University, Poznań, Poland.
Background: The purpose of this study is to determine the effect of the type of I-125 radioactive source on dose distribution in the planning process of ultra-low dose rate (uLDR) prostate brachytherapy.
Material And Methods: 7 patients who had undergone brachytherapy in our center were included in the study. Dose in five geometrical points were analyzed for 12 types of implants that are available on the market.
Optimized chelator and nanoparticle strategies for high-activity Pd-loaded biodegradable brachytherapy seeds.
EJNMMI Radiopharm Chem
December 2024
The Hevesy Laboratory, DTU Health Technology, Frederiksborgvej 399, 4000, Roskilde, Denmark.
Background: Brachytherapy (BT) is routinely used in the treatment of various cancers. Current BT relies on the placement of large sources of radioactivity at the tumor site, requiring applicators that may cause local traumas and lesions. Further, they suffer from inflexibility in where they can be placed and some sources reside permanently in the body, causing potential long-term discomfort.
View Article and Find Full Text PDFA prospective comparison of implant quality between suture-coated seeds and uncoated seeds in prostate cancer brachytherapy.
J Contemp Brachytherapy
October 2024
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
Purpose: Displacement minimization of seeds is crucial during surgery in brachytherapy; however, only a few reports have compared the operability of different seeds. TheraStrand-SL is a seed, in which TheraAGX100 is wrapped in polyglactin 910 thread, and intra-prostatic displacement is expected to be reduced compared with that of Thera-AGX100, owing to the complex shape of TheraStrand-SL. We conducted a prospective study on the operability and treatment outcomes of TheraAGX100 and TheraStrand-SL placement by a single operator.
View Article and Find Full Text PDFHydrogen-Generating Magnesium Alloy Seed Strand Sensitizes Solid Tumors to Iodine-125 Brachytherapy.
Adv Sci (Weinh)
December 2024
Department of Minimally Invasive Intervention, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Radioactive iodine-125 (I) seed implantation, a brachytherapy technique, effectively kills tumor cells via X-rays and gamma rays, serving as an alternative therapeutic option following the failure of frontline treatments for various solid tumors. However, tumor radioresistance limits its efficacy. Hydrogen gas has anticancer properties and can enhance the efficacy of immunotherapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!